Mildronate and Multiple Sclerosis

In 2008, led by Professor T. Matveeva (Kazan), work was undertaken to study the possibility of using Mildronate as an antioxidant in complex therapy of different variants of multiple sclerosis (MS). The study included patients with MS (cerebrospinal form) of both sexes, average age 40,2 ± 2,7 years, mean disease duration 7,20 ± 1,58 years.

The treatment regimen consisted of:

- Mildronate 500 mg / day / m (group 1) within 10 days;

- Mildronate (Meldonium) 500 mg / day / m (group 2) for 10 days, 21 days further inwards;

- Mildronate 500 mg / day / m + GCS scheme (Dexamethasone) (group 3) within 10 days;

- Mildronate (Meldonium) 500 mg / day / m + GCS scheme (Dexamethasone) (Group 4) for 10 days, 21 days further inwards;

- Control group - GCS scheme (Dexamethasone) without Mildronats.

As a result of this work was concluded:

1. The value of the degree of disability of MS patients resulting in decreased Mildronate therapy compared with the control group, with Mildronate application regimen / m + Mildronate inside was more effective.

2. A significant reduction in the degree of disability in Mildronate group recorded with relapsing-remitting nature of MS, while the figure swelled in the control group.

3. Application Mildronate reduced the value of the EDSS during the 1st and 2nd stage of MS.

4. it was found that the use of Mildronate (Meldonium) reduces performance in pyramidal, cerebellar and sensory systems In assessing functional for Kurtske systems.

5. Application Mildronate in conjunction with Gluco-cortico-steroids (GCS) for the relief of acute MS reduced the degree of disability of MS patients, with a significantly increased gap between the initial and final degree of disability as compared to a group of corticosteroids without Mildronate.

6. Comparison of treatment regimens Mildronate / m + Mildronate PER os + GCS and Mildronats PER os + GCS revealed that the application form Ampouled Mildronate followed by a continuation of oral administration is more efficient compared with the scheme Mildronate (amp.) + Corticosteroids.

7. Mildronate is more effective with a favorable type of MS, while the degree of disability in unfavorable type has remained virtually unchanged.

8. Mildronate therapy improved quality of life, physical and mental health of people with MS.

9. Mildronate (Meldonium) treatment has an impact on all components of the health of patients.